GlassScriptPhysician profile
Elaina Fearer
NPI 1467154997
$2,130.81
in general payments reported to CMS, 2019-2025
26 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $915 · 2024: $713 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $280.89 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $270.16 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $250.25 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $215.30 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $202.70 | 2023-2025 | |
| Abbvie INC. | $198.00 | 2023-2025 | |
| Amgen INC. | $74.23 | 2024-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $73.97 | 2023-2024 | Veozah |
| Dexcom, INC. | $68.93 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $61.31 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.42 | 2023 | |
| Esperion Therapeutics, INC. | $51.88 | 2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $38.24 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.23 | 2023 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $34.51 | 2024-2025 | Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $32.50 | 2023 | Heplisav-B |
| Daiichi Sankyo INC. | $27.33 | 2023 | Injectafer |
| Abiomed | $20.24 | 2023 | Impella |
| Actelion Pharmaceuticals US, INC. | $19.86 | 2023 | Uptravi, Opsumit |
| Exact Sciences Corporation | $19.71 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $18.73 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2025 | Jardiance |
| Seqirus USA INC | $16.10 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Nestle Healthcare Nutrition INC. | $15.81 | 2023 | |
| Merck Sharp & Dohme LLC | $15.35 | 2024 | Vaqta, Gardasil 9, Gardasil |
| Shield Therapeutics INC | $13.51 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaina Fearer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.